Practitioners’ Guide for Improving Oral Anticoagulant Use

About This Site:

This activity is supported by the U.S. Food and Drug Administration (FDA) through a contract from the U.S. Department of Health and Human Services. FDA's privacy policy applies while you are on this site.

This course can be taken for informational purposes or for Continuing Education (CE) credit.

Continuing Education Credits (CE) released: 06/01/2020; Valid for credit through: 06/01/2023

Certificates of Completion:

For users wishing to have confirmation that they have completed this course, they may choose to receive a Certificate of Completion which comes with no CE credits.

Target Audience:

The target audience for this course is healthcare professionals, including physicians, physician assistants, nurses, nurse practitioners, pharmacists, and pharmacy technicians. The course can be taken for informational purposes or for Continuing Education (CE) credit.

Description:

This online course will educate a national audience of healthcare providers about improving anticoagulant use.

Satisfactory Completion:

Learners must listen to each self-directed audio recording while following along with the visual slides/read the articles, pass the post-test with a score of 70% or higher and/or complete an evaluation form to receive a certificate of completion or CE credit. You must participate in the entire activity as partial credit is not available.

NOTE: If you are seeking CE credit for a specialty not listed on this page, it is your responsibility to contact your licensing/certification board to determine eligibility for your licensing/certification requirement.

Learning Objectives:

Upon completion of this activity, participants will be able to:

  • Discuss the prevalence and types of adverse drug events related to oral anticoagulants.
  • Review the drug classifications of oral anticoagulants.
  • Compare characteristics of oral vitamin K antagonists and direct acting oral anticoagulants.
  • Identify pathophysiological states for utilization of oral anticoagulation therapy.
  • Review barriers to proper oral anticoagulant use.
  • List steps that clinicians can take to reduce the risk of adverse drug events from oral anticoagulants.

Acknowledgement of Financial Commercial Support:

No financial commercial support was received for this educational activity.

Acknowledgement of In-Kind Commercial Support:

No in-kind commercial support was received for this educational activity.

Disclosure Information

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content of CME disclosed to Amedco. All of these relationships were treated as a conflict of interest and have been resolved. (C7 SCS 6.1--6.2, 6.5).

All individuals in a position to control the content of CE/CME are listed below and had no relevant financial relationship to disclose.

First NameLast NameDisclosure
FranCunninghamNothing to disclose
EllenEckesNothing to disclose
ElaineFrostNothing to disclose
MaryGeorgeNothing to disclose
MaryGhodsNothing to disclose
LisaLongoNothing to disclose
SophiaNiNothing to disclose
ClydettePowellNothing to disclose
RachelShawNothing to disclose
AnitaThomasNothing to disclose
VictoriaWilsonNothing to disclose
ScottWinieckiNothing to disclose
JoyceYuNothing to disclose

Handouts and Resources:

Accreditation Statement:

Jointly Accredited Provider Logo

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and the U.S. Food and Drug Administration (FDA). Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Credit Designation Statement:

Amedco LLC designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)TM for physicians. Learners should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Credit Designation Statement:

Amedco LLC designates this enduring material for a maximum of 1 knowledge-based contact hours for pharmacists. Learners should claim only the credit commensurate with the extent of their participation in the activity. UAN(s): JA4008163-9999-20-054-H04-P, JA4008163-9999-20-054-H04-T

NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of the activity to meet the deadline for submission to CPE Monitor.

Nurse Credit Designation Statement:

Amedco LLC designates this enduring material for a maximum of 1 contact hours for nurses. Learners should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioner Credit Designation Statement:

AANP Accredited Stamp

This activity is approved for 1.0 contact hour(s) of continuing education (which includes 1.0 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 20054263. This activity was planned in accordance with AANP Accreditation Standards and Policies.

Physician Assistant Credit Designation Statement:

American Academy of PAs Logo

Amedco has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until June 1, 2023. PAs should only claim credit commensurate with the extent of their participation.

Technical Requirements and Instructions:

To access the course, users will need a computer with an Internet connection, and:

  • Internet Explorer 10 or higher,
  • Firefox 43 or higher,
  • Safari 9 or higher, or
  • Any other W3C standards compliant browser

An HTML5 capable browser is required for video playback. Occasionally, other additional software may be required such as Microsoft PowerPoint or Adobe Acrobat Reader. Viewing on a desktop, laptop, or tablet is recommended.

This is a responsive course. Parts of the course may display differently across various devices and screen resolutions. Scrolling may be required in some instances.

Users are required to view the entire course before getting access to the post-test. To receive your certificate for CE credit or certificate of completion, you must complete the post-test and receive a score of 70% or better and complete an evaluation form.

For questions about content or about technical issues, you may contact FDA:

Toll Free
(855) 543-3784, or
(301) 796-3400
druginfo@fda.hhs.gov